急性白血病血浆GMP-140和vWF检测及其临床意义

采用ＥＬＩＳＡ法测定３２例急性白血病患者血浆血小板α颗粒膜蛋白（ＧＭＰ－１４０）和血管性假血友病因子（ｖＷＦ）水平。结果发现，初治和复发患者血浆ＧＭＰ－１４０、ｖＷＦ浓度较正常对照显著升高（Ｐ＜０．０１），完全缓解后明显下降至正常水平；血浆ＧＭＰ－１４０与ｖＷＦ浓度间呈显著正相关，外周血白血病细胞数与血浆ＧＭＰ－１４０浓度间呈显著正相关。结果提示，急性白血病患者体内存在血小板活化程度增高、血管内皮细胞受损等病理改变。检测血浆ＧＭＰ－１４０和ｖＷＦ水平有助于疾病严重程度的了解及预后的评估。

THE SIGNIFICANCE OF MEASURING GMP 140 AND vWF IN PATIENTS WITH ACUTE LEUKEMIA

By using ELISA assay, alpha granule membrane protein (GMP 140) and von willebrand factor (vWF) in plasma were measured in 32 patients with acute leukemia. The results showed that the level of GMP 140 and vWF in plasma increased significantly in untreated patients with acute leukemia compared with normal controls(P<0.01) and reduced to normal range in complete remission patients. There were correlation between the level of GMP 140 and vWF in plasma, the level of GMP 140 in plasma and the amount of blast cell in peripheral blood. The results suggested that there were damage of endothelial cell and increasingly activated platelet in patients with acute leukemia. This indicated that the level of GMP 140 and vWF in plasma might be helpful for assessment of the severity of disease and estimation of prognosis.